Several clinical trials of bone marrow cell infusion in patients with liver cirrhosis (LC) have shown clinical improvement, despite conflicting results from animal models. We investigated serial pathological features and the clinical impact after autologous bone marrow infusion (ABMI) in patients with advanced LC. Ten patients with advanced LC due to chronic hepatitis B virus infection underwent ABMI. Serological tests, MRI, and liver biopsies were performed, and quality of life was assessed by a questionnaire. Median serum albumin and hemoglobin levels increased significantly after ABMI. All patients showed an improvement in quality of life, with no serious adverse events. Liver volume, measured by MRI, increased in 80% of the patients, and ascites decreased after ABMI. Child-Pugh scores were also significantly improved at 6 months after ABMI. In the serially biopsied livers, a gradually increasing activation of the hepatic progenitor cell (HPC) compartment, including HPC activation (ductular reaction) and HPC differentiation (intermediate hepatocyte), reached a peak after 3 months, with continued proliferation of hepatocytes, and returned to baseline levels after 6 months. There was no significant change in grade or stage of liver fibrosis or stellate cell activation after ABMI. ABMI is suggested to improve liver function and to activate the progenitor cell compartment. Although clinical improvement was sustained for more than 6 months, histological changes in the liver returned to baseline 6 months after ABMI. Further comparative studies are warranted.
INTRODUCTION
high cost, regenerative therapy has been suggested to provide alternative choices using less invasive procedures. Liver cirrhosis (LC) is the end stage of various chronic liver diseases and is extremely difficult to treat.
In general, organ regeneration requires the presence of a progenitor cell population in the absence of a resi-In addition to substitution of parenchyma by fibrous tissue, the gradual loss of cellular function results in the dent cell proliferation (15) . However, in the liver physiological turnover and regeneration occur predominantly impairment of homeostasis. Until now, liver transplantation has been the only effective method of cure, but due through replication of native hepatocytes. Progenitordependent regeneration takes place only if parenchymal to the several limitations of transplantation, such as a lack of donors, surgical complications, rejection, and hepatocytes are severely damaged and unable to regen-1238 KIM ET AL. erate efficiently, as in cirrhosis (17) . Thus, as an external We advised all patients to maintain their current medications, except diuretics, during the study period. After source of hepatocytes, mature hepatocytes, fetal hepatocytes, oval cells (hepatoblasts in humans), hematopoietic ABMI, doses of diuretics were adjusted according to the patient's condition. Antiviral therapy was individual-stem cells, mesenchymal stem cells, multipotent adult progenitor cells, or embryonic stem cells have been used ized, according to the guidelines. No patient was given albumin during the study. for regeneration in liver disease models (4).
After Peterson and colleagues (19) first reported bone BMC Harvest and Infusion marrow cells (BMCs) as a potential source of oval cells, supportive data about bone marrow-derived hepatocytes BMCs (500-750 ml) were harvested from both ilia according to standard procedures under general anesthe-in animals (12,28) and humans (1) have been published. Although recent advances have documented that bone sia and were collected in a plastic bag containing heparin. After fat and bony particles were removed by filtra-marrow cells can also differentiate into muscle (5), heart (16) , pancreas (9), and lung (8) cells, controversy still tion, collected cells were moved to a cell-processing device. The automatic cell washer 2991 (Gambro, Lake-exists regarding the role of BMCs in organ regeneration, including in the liver. Researchers who have a negative wood, CO, USA) was used for collecting mononucleated cells (MNCs), as well as depleting red blood cells and opinion on the plasticity of BMCs insist that little evidence exists for the use of bone marrow-derived hepato-plasma in a closed system. The final concentrated cell product was made up to a final volume of about 100 ml. cytes in the replacement of injured liver (10), and that no data have demonstrated transdifferentiation to hepa-Five milliliters of the final cell product was subjected to trypan blue dye exclusion testing, bacterial culture, cell tocytes or a major role in regeneration (14, 30, 31) . On the other hand, BMCs have been reported to be a possi-counting, and fluorescence-activated cell sorting analysis by flow cytometry (Cytomics FC 500; Beckman ble source of functional hepatic stellate cells and myofibroblasts contributing to fibrosis (23).
Coulter, Inc., Fullerton, CA, USA). Because no specific cell marker has been proven useful in estimating con-However, in a murine model, transplanted BMCs populated and differentiated into albumin-producing he-tributing cells for hepatic regeneration, hematopoietic stem cell markers (CD34, CD45, CD133; Miltenyi Bio-patocytes, via hepatoblast intermediates (27). Furthermore, in humans, BMC infusion elevates serum albumin tech, Inc., Auburn, CA, USA) and an epithelial cell marker (CD 117; Immunotech, Beckman Coulter, Mar-levels (26), and, in mice or rats, it reduces liver fibrosis (7), corrects liver dysfunction (2), and improves survival seille, France) were used to assess cell composition. At 4-8 h after harvesting the BMCs, the final MNC prepa-rate (25). Based on these results, a clinical trial of autologous BMC infusion (ABMI) has been performed ration was administered into a peripheral vein over a 1h infusion. (18, 24) , and it was shown that ABMI administered through a peripheral vein or the hepatic artery improves Clinical Follow-up Protocol liver function in patients with LC (13,26).
Although recent clinical trials have shown transient Before ABMI, laboratory tests with MRI and liver biopsy were conducted. After ABMI, patients were dis-improvements in liver function, there has been no report about the duration of effect and what happens in the charged within 5 days and followed up every week for 2 weeks, and monthly for 6 months. Laboratory tests, liver after cell transplantation. The aims of this study were to investigate the clinical impact and serial histo-body weight check, and a questionnaire for performance status, subjective well-being, and quality of life were logical changes that contribute to liver regeneration and to determine how long such changes were sustained checked at every visit. Performance status was scored using a 0-100% grading scale. Subjective well-being after ABMI in patients with advanced LC. and quality of life were scored using a 1-7 grading MATERIALS AND METHODS scale. Indocyanine green clearance was also measured Patients before and 1, 3, and 6 months after the procedure. Patients were enrolled between November 2006 and MRI Evaluation February 2008. All patients had biopsy-proven LC. Child-Pugh class B or C patients aged between 18 and All MRI to measure liver volume and ascites, and to screen for HCC, was performed using 1.5-T MR scan-75 years with total bilirubin ≤3.0 mg/dl, platelet count ≥50,000/µl, and no viable hepatocellular carcinoma ners (Gyroscan Intera; Philips Medical Systems Best, The Netherlands). Routine T1-weighted gradient echo, (HCC) on magnetic resonance imaging (MRI) were eligible. Patients were excluded from the study if they had T2-weighted turbo spin echo, T2*-weighted gradient echo, and three-phase, dynamic three-dimensional (3D) problems with organs other than the liver, required general anesthesia, or had any uncontrolled malignancies.
T1-weighted images after injection of gadobenate di-meglumine (dose: 0.1 mmol/kg of body weight; Multi-evaluated on p21-stained sections and the p21 labeling index was determined as the percentage of positive nu-Hance; Bracco SpA, Milan, Italy) were obtained.
The total liver volume was measured with commer-clei per total number of nuclei counted in at least five non-overlapping HPFs. Stellate cell activation was eval-cially available image postprocessing software (Voxel plus 2; Mevisys, Daeduk, Korea) using the summation-uated in smooth muscle actin-stained sections. Activated hepatic stellate cells were evaluated semiquantitatively, of-areas technique with a 10-mm reconstruction thickness by one radiologist. Right perihepatic ascites was as follows: grade 0, no positive cells; 1+, rare positive cells that required a careful search at high power; 2+, estimated by a 3D measurement [the largest length (x) of ascites × the greatest perpendicular length (y) × sum scattered positive cells readily identified at medium power; 3+, scattered or clustered positive cells apparent of the vertical length (z)] on a picture archiving and communication system (PACS) monitor by another radi-at low power; 4+, widespread positive cells apparent at low power. ologist. The radiologist was unaware of the patient history, laboratory results, or biopsy findings.
Statistical Analyses Liver Biopsy, Tissue Preparation,
Changes in clinical indices from baseline to months and Immunohistochemistry after ABMI were analyzed. Wilcoxon's signed-ranks Liver biopsies were performed before and 1, 3, and 6 test with Bonferroni correction was used to compare the months after ABMI using an ultrasound-guided 16- values of paired samples. Descriptive statistics were also gauge gun, if the patient consented. Transjugular liver used. Changes in proportion from baseline to last folbiopsy was attempted as an alternative biopsy in cases low-up were plotted and compared. The analyses were with massive ascites or a high risk of bleeding. performed using the SPSS 13.0 statistical package The biopsied liver tissues were routinely processed (SPSS Inc., Chicago, IL, USA). All statistical analyses and hematoxylin and eosin (H&E) stained. Tissue secwere based on two-tailed hypothesis tests with a signifitions (4 µm) of formalin-fixed, paraffin-embedded liver cance level of p < 0.05. specimens were deparaffinized with xylene and rehydrated through graded alcohols. After washing in dis-Ethical Considerations tilled water, the sections were immersed in 3% hydrogen peroxide to block endogenous peroxidase activity. Anti-
The protocol for the clinical trial conformed to the gen retrieval was performed by boiling the sections in ethical guidelines of the Declaration of Helsinki and was 100 mM sodium citrate (pH 6.0) for 15 Table 1 . The me-(HPFs; ×400), and the average of these scores/HPF was taken. The proliferating hepatocytes were evaluated in dian age was 56 (range 43-64) years old. Three patients were male and seven were female. All patients had a PCNA-stained sections; the hepatocytes with nuclear PCNA expression were counted in at least five non-history of ascites, and four patients had ascites at enrollment. All patients had Child-Pugh class B cirrhosis. overlapping HPFs, and the average of these scores/HPF was taken. The hepatocytes in replicative arrest were Eight of the 10 patients had been on antiviral treatments, with oral nucleoside/nucleotide analogs. All patients Changes in Clinical Data were positive for HBsAg and negative for antibodies against hepatitis C.
Serial clinical data from each patient were recorded. The initial median albumin level at screening was 2.7 g/ Characteristics of Processed Total dl. The median albumin level during the 6 months be-Mononucleated Cells fore ABMI was 2.9 g/dl, and this slightly decreased with conservative management, including use of antiviral Infused MNC characteristics and composition, according to cellular markers, are summarized in Table 2. agents. Beginning at the first month after ABMI, the serum albumin levels gradually increased and reached at The median infused MNC count per body weight was 0.995 × 10 8 cells/kg (range, 0.48-1.48 × 10 8 ). The me-peak level to 3.5 g/dl at 9 months, which was maintained at 12 months after ABMI. Significant increase was noted dian infused volume of concentrated MNCs was 112.5 ml (range, 88-150). CD45-positive hematopoietic stem at 6 months after ABMI (Fig. 1A) . The median hemoglobin level showed a gradual but significant increase at cells were the major cell component (median, 79.85%). CD133-positive hematopoietic stem cells composed each time point, from 11.7 g/dl at baseline to 13.8 g/dl at 12 months after ABMI (Fig. 1B) . The median choles-1.05% of total infused cells. CD34-positive stem cells and CD117-positive epithelial cells represented 0.53% terol level improved significantly at 6 and 12 months after ABMI (Fig. 1C) . The median prothrombin time and 1.0% of infused cells, respectively. tended to improve; a significant difference was seen Child-Pugh score improved significantly after 6 months (Fig. 1E) ; however, there was no change in MELD only at 6 months after ABMI (Fig. 1D ). Serum alanine aminotransferase, total bilirubin, and α-fetoprotein lev-scores. Performance status reflecting objective daily activity, subjective scoring about feeling of well-being els showed no statistically significant change. The (Fig. 1F ), and quality of life increased significantly at 6
Liver biopsy at 6 months after ABMI showed a decrease in the HPC compartment to baseline levels. This pattern months, at 6 and 12 months, and at 6 months after ABMI, respectively. of HPC compartment activation was consistent in all patients ( Fig. 4) .
Changes in Liver Volume and the Amount of Ascites,
The proliferating hepatocytes showed nuclear expresby MRI sion of PCNA. The mean number of proliferating hepatocytes per HPF gradually increased after ABMI and Hepatic volumes before and at 6 months after ABMI were compared. The median liver volume increased by peaked at 3 months after ABMI (Fig. 4B ). The number of hepatocytes in replicative arrest was evaluated using 5% after 6 months of ABMI (Fig. 2) . Patient 1's liver, in particular, grew by 42% in the 6 months after ABMI. the p21 labeling index (Fig. 4C ). The p21 labeling indexes were very low, and the maximal value was less The relative amount of ascites between baseline and the last visit was also compared. Among four patients than 3.5% in all serially biopsied liver tissues; there was no significant change before and after ABMI. with ascites at baseline, three showed a decreased amount of ascites in spite of reduction or discontinuation All liver biopsies at baseline and after ABMI showed cirrhosis with mild necroinflammatory activity. There of diuretics. The amount of diuretics required was reduced in all patients without weight gain or peripheral was no significant change in grade or stage of cirrhosis in the serially biopsied livers after ABMI. Additionally, edema. None of the patients developed new ascites.
stellate cell activation was grade 2+ in most biopsies, Liver Pathological Features in Serially Biopsied Liver and there was no significant alteration in the activation of stellate cells among baseline and serially biopsied liv-The HPC compartment, including HPC activation (ductular reaction) and HPC differentiation (intermedi-ers after ABMI in any patient. ate hepatocytes), which showed a positive reaction for Toxicity and Complications cytokeratin-7, was evaluated at baseline and in serial liver biopsies after ABMI (Fig. 3) 
. The baseline liver
No serious adverse events occurred during or after ABMI. Two patients complained of pain at the puncture biopsy in all patients showed a low level of HPC activation and differentiation. The HPC compartment showed site on the first day, which subsided without medication. a gradual increase in all patients after ABMI. It peaked DISCUSSION at 3 months after ABMI and there were 1.4-6.8-fold increases, when compared with the baseline liver biopsy.
We found that ABMI could induce clinical improvement and increase HPC and hepatocyte proliferation in patients with advanced cirrhosis. To our knowledge, this is the first report to show serial clinicopathological changes, such as activation of the liver progenitor cell compartment, and to reveal how long these alterations were sustained after ABMI. We also demonstrated clinical improvements, consistent with previous data (3, 13, 26) .
Clinical trials of ABMI in chronic liver disease have begun in a few institutes, although the basic mechanism of hepatic regeneration is unclear in the human liver. Peripheral infusion of concentrated autologous BMCs has been reported to improve liver function in patients with cirrhosis (13,26). In this study, we also found that it could improve liver function and quality of life, with objective liver volume increases in patients with advanced LC. The increase in liver volume was especially marked in patient 1, who showed a final liver volume 1.42-fold larger than the initial volume. This patient had undergone a right lobectomy due to HCC 16 months before the ABMI, which was a distinct clinical history situations, evokes a rapid regenerative response to re-improved in all patients, and all experienced a better sense of well-being and complained less about fatigue, store liver volume (6), we suspect that a suboptimal regeneration after a previous partial resection of the liver although we could not completely rule out a placebo effect. In this study, among various clinical parameters, may alter the effect of ABMI on the patient's liver growth. Although in our study total MNCs were infused because serum albumin and ascites were improved remarkably, Child-Pugh score had improved significantly, via a peripheral administration route at a different time point long after the operation, the portal administration but not MELD score. As factors constituting Child-Pugh score include albumin and ascites, not MELD score but of autologous CD133-positive BMCs before an operation also accelerates liver regeneration and is a novel Child-Pugh score had improved. Although there was no remarkable change in liver pathology except progenitor therapy supporting hepatic resection (3).
Serum albumin as the most important marker of he-cell compartment, functional improvement was noted. Activation of progenitor cell compartment after ABMI patic function and hemoglobin showed a gradual increase and reached a significant level from 1 month after seen in liver pathology might result in increase of functional hepatocytes. And we can guess these hepatocytes ABMI. These findings were sustained up to 12 months, although liver biopsies showed that significant activa-could contribute clinical improvements, such as increase in albumin. tion of progenitor cell compartment had lasted only for 3 months. Serum cholesterol and prothrombin time as All of the patients had hepatitis B virus-related cirrhosis. Eight patients had been receiving antiviral treat-other markers representing hepatic function also showed improvement. In four patients who had ascites initially, ment before the procedure, and two patients started antiviral therapy after the procedure. Under antiviral the amount decreased, even after reducing the dose of diuretics. This is also an indirect marker of hepatic func-treatment, the viral level was well controlled in most patients. Because there was some doubt that antiviral tional improvement. Quality of life and daily activities therapy contributed to the clinical improvement, we compared serum albumin levels during the 6 months prior to ABMI and 6 months after ABMI. There was no improvement in serum albumin levels during the 6 months prior to ABMI, whereas levels rather prominently increased in the same period after ABMI. Furthermore, two patients who started antiviral therapy after ABMI did not contribute more significantly to the changes relative to the remainders who had previously received antiviral therapy. Thus, ABMI seemed to have a major effect on these changes. However, we cannot exclude additive desirable effects of antiviral therapy on these clinical and histological changes, because antiviral treatment has been shown to improve clinical state and liver fibrosis. If there is synergistic or additive effect of ABMI and antiviral therapy, ABMI would be more effective especially in HBV-related cirrhosis.
We found that the HPC compartment, including HPC activation (ductular reaction) and HPC differentiation (intermediate hepatocytes), showed a gradual increase after ABMI in serially biopsied livers. The ductular reaction represents activated progenitor cells, which are thought to correspond to oval cells or oval-like cells in rodents. These cells can differentiate toward functioning hepatocytes through intermediate cells, which are phenotypically between hepatocytes and cholangiocytes (20, 21, 29) . Activation of the HPC compartment has been well documented in acute, subacute, and chronic severe liver injury, when the regeneration of mature hepatocytes is impaired and lost (11). All cirrhotic patients in this study showed a low level of activation of the HPC compartment in the baseline liver biopsy that clearly increased after ABMI. Activation of the HPC compartment peaked at 3 months after ABMI, with a 1.4-6.8-fold increase compared to the baseline liver biopsy. After 6 months, they returned to baseline levels.
Another important cell in liver regeneration is the proliferating hepatocyte. The PCNA labeling index of mature hepatocytes showed a gradual increase, with a helpful in patients with advanced LC as a bridge therapy before liver transplantation. Further comparative studies peak at 3 months after ABMI. The maximal value was five times higher than the baseline biopsy. These prolif-are warranted. erating mature hepatocytes are considered to contribute bution of liver fibrosis and large cirrhotic nodules. In
